Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Strategic Expansion into AI-Powered Healthcare Solutions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mustang Bio Inc MBIO

Healthcare Biotechnology
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene... see more

Recent & Breaking News (NDAQ:MBIO)

Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

GlobeNewswire May 12, 2022

Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress

GlobeNewswire May 12, 2022

Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting

GlobeNewswire May 3, 2022

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

GlobeNewswire April 25, 2022

Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations

GlobeNewswire April 21, 2022

Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma

GlobeNewswire April 13, 2022

Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

GlobeNewswire April 4, 2022

Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022

GlobeNewswire April 1, 2022

Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

GlobeNewswire March 23, 2022

Mustang Bio to Participate in Three March 2022 Investor Conferences

GlobeNewswire March 10, 2022

Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children's Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

GlobeNewswire March 9, 2022

Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital

GlobeNewswire March 8, 2022

Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium

GlobeNewswire February 15, 2022

Mustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact Awards

GlobeNewswire February 8, 2022

Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency ("XSCID") in Previously Transplanted Patients

GlobeNewswire January 24, 2022

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

GlobeNewswire January 7, 2022

Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences

GlobeNewswire January 5, 2022

Mustang Bio Added to the NASDAQ Biotechnology Index

GlobeNewswire December 16, 2021

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

GlobeNewswire December 13, 2021

Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

GlobeNewswire December 9, 2021